The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


European Medicines Agency recommends Janssen Velcade to treat mantle cell lymphoma.....           Dr. Reddy?s Laboratories buys Habitrol brand from Novartis.....           MSD launches posaconazole concentrate for solution for IV in UK.....           Roche's bid to sub Kadcyla for Herceptin takes a big hit with lackluster PhIII data.....           China promises faster drug approvals, equal treatment for U.S. companies.....           Salix investors pushing for sale once supply issues wrap.....           Orexigen's weight-loss drug gets thumbs-up from CHMP.....           Novo Nordisk gets EU recommendation for Tresiba use in kids.....           Established product sales lacking in pharma's whopper M&A year.....           Deal-happy Actavis eyes Spain's Almirall for European growth: Bloomberg.....           Valeant Canada secures rights of hypertension drugs Edarbi and Edarbyclor from Takeda.....           Cerulean doses first patient in Phase I/IIa trial of CRLX301 to treat advanced solid tumors.....           AstraZeneca's Lynparza gets European approval to treat BRCA-mutated ovarian cancer.....           KCR buys Ukrainian CRO AXIS? project portfolio.....           GlaxoSmithKline reports positive results from Phase III trial of shingles candidate vaccine.....           Bayer files BLA for BAY 81-8973 to treat Hemophilia A in adults and children.....           Pfizer reports positive results from phase III trial of Pregabalin.....           BioCryst begins OPuS-2 clinical trial of BCX4161 to treat patients with Hereditary Angioedema.....           Enumeral, Merck to predict clinical drug response with human-driven immune profiling platform.....           Aldeyra Therapeutics submits FDA IND filing for noninfectious anterior uveitis.....           Merck to acquire Swiss biotechnology firm OncoEthix.....           Valeant Canada secures rights of hypertension drugs Edarbi and Edarbyclor from Takeda.....           Cerulean doses first patient in Phase I/IIa trial of CRLX301 to treat advanced solid tumors.....           AstraZeneca's Lynparza gets European approval to treat BRCA-mutated ovarian cancer.....           KCR buys Ukrainian CRO AXIS? project portfolio.....           GlaxoSmithKline reports positive results from Phase III trial of shingles candidate vaccine.....           Bayer files BLA for BAY 81-8973 to treat Hemophilia A in adults and children.....           Pfizer reports positive results from phase III trial of Pregabalin.....           BioCryst begins OPuS-2 clinical trial of BCX4161 to treat patients with Hereditary Angioedema.....           Enumeral, Merck to predict clinical drug response with human-driven immune profiling platform.....           Aldeyra Therapeutics submits FDA IND filing for noninfectious anterior uveitis.....           Merck to acquire Swiss biotechnology firm OncoEthix.....           NutraFuels receives purchase order from RC Taylor distributing.....           iCardiac Technologies IQ-CSRC study shows potential for faster drug development.....           FDA accepts filing Apotex's biosimilar application for pegfilgrastim.....           Halozyme, Janssen to develop and commercialize products using Enhanze technology.....           Clementia begins natural history trial in FOP patients.....           CannaPharmaRx, PharmaDirections to start research & discovery program in Cannabinoid Science.....           BioBlast receives notice of patent issuance for new fusion protein-based platform to treat Friedrich's Ataxia.....           Iodine launches cold and flu app to helps smart consumers find best OTC options for their symptoms.....           NutraFuels receives purchase order from RC Taylor distributing.....           iCardiac Technologies IQ-CSRC study shows potential for faster drug development.....           Wishing, hoping, planning as AbbVie's hep C do-or-die moment nears.....           AstraZeneca snags EU approval for first-in-class cancer fighter Lynparza.....           Indictment of 14 at NECC includes murder charges.....           Flush-with-cash Shire revisits deal for NPS Pharma.....           GlaxoSmithKline's shingles shot scores in 16,000-patient study.....           GlaxoSmithKline CEO: Chin up, investors. Dividend's safe, and Novartis deal awaits.....           Pfizer begins Phase II trial of PF-06252616 to treat duchenne muscular dystrophy.....           Ossianix and Lundbeck agree to research collaboration expansion on CNS therapeutics.....           BioLineRx, Novartis to develop and commercialize Israeli-sourced drug candidates.....           HedgePath gets FDA nod to begin proposed cancer drug development.....           DURECT grants worldwide rights of SABER ophthalmology product to Santen.....           Boston Strategics, MD Anderson to conduct Phase I/IIa trial of leukemia drug E6201.....           Novogen announces breakthrough discovery melanoma treatment.....           PPD, ERT partner to improve drug development.....           Portage further validates new proprietory cell permeable peptide platform technology.....           Lightlake enters into license agreement with Adapt Pharma Operations.....           The top 10 patent losses of 2015.....           Belgium's UCB calls it quits on $1.53B sale of U.S. generic drug unit.....           Novartis sues Cipla for ignoring its COPD drug patents.....           Gilead chief racks up best-CEO laurels for Sovaldi-fueled 2014.....           Mylan, Actavis prevail in Celebrex exclusivity fight, pushing Teva aside.....           Pfizer, Bayer and Boehringer meds win backing from U.K. cost agency.....           Court's decision on Namenda 'hard switch' could spill over into precedent.....           Novartis? Signifor LAR obtains FDA approval to treat acromegaly.....           New European consortium to help advance development of GSK/NIH Ebola vaccine candidate.....           NICE recommends Boehringer's Pradaxa to treat and prevent recurrence of DVT and PE.....           FDA approves Ipsen?s Somatuline Depot Injection to treat GEP-NETs.....           CSL Behring seeks FDA approval for rIX-FP to treat hemophilia B patients.....           Yew Bio-Pharm to enter US health supplement market with two agaric polysaccharide products.....           Collegium seeks FDA approval for Xtampza ER to treat chronic pain.....           Boehringer enrolls first patient in Phase III RE-SPECT ESUS trial of dabigatran.....           Fresh off Afinitor failure, Novartis turns tide with Signifor LAR approval.....           New Actavis chief sweeps aside most top Allergan execs.....           FTC plows ahead in pay-for-delay suit over AbbVie's AndroGel.....           Roche's Lucentis nabs FDA 'breakthrough' tag for diabetic eye disease.....           Salix expects lackluster sales as it speeds to fix inventory issues.....           Point-of-care marketing shoots past DTC as pharma's latest marketing trend.....           Pfizer to develop and commercialize OPKO's long-acting human growth hormone.....           ViiV Healthcare seeks Japan's approval for combination drug to treat HIV.....           Prothena's AL amyloidosis treatment NEOD001 gets FDA fast track status.....           Sorrento, Nantworks to jointly develop next generation cancer immunotherapies.....           Advaxis gets FDA clearance to begin Phase I/II trial of combination cancer therapy.....           Baxter to divest Vero Cell vaccines platform to Nanotherapeutics.....           Microchips completes development, clinical demonstration of drug delivery platform.....           Pfizer reports positive Phase II PALOMA-1 trial of palbociclib.....           Actavis will appeal injunction requiring continued distribution of NAMENDA IR.....           American Regent's injectafer assigned J Code by Centers for Medicare & Medicaid Services.....           Mettrum gets Health Canada license at its Agripharm facility.....           FDA approves two higher dosage strengths of Orexo's ZUBSOLV.....           Pacira Pharmaceuticals announces changes to EXPAREL label.....           FDA approves Merck's HPV vaccine GARDASIL9.....           Boehringer releases positive results from two breast cancer trials of afatinib.....           CA panel: Gilead's Harvoni cost-effective at $95K, but only affordable at half the price.....           Bayer fails last-ditch attempt to block India's cheap Nexavar copies.....           Stada, Dr. Reddy's and others dodge German drug suspensions with appeals.....           Banks lost big betting on canceled AbbVie-Shire merger.....           Turnaround-minded Teva CEO scouts deals in specialty generics, emerging markets.....           Bayer runs into another German roadblock in marketing vision drug Eylea.....           US FDA approves Lilly's Cyramza to treat aggressive non-small cell lung cancer.....           Jazz begins rolling NDA submission for defibrotide to treat severe hepatic VOD.....           Immunovaccine receives FDA fast track status for DPX-Survivac to treat ovarian cancer.....           Karyopharm doses first patient in Phase IIb trial of selinexor to treat DLBCL.....           FDA approves Sanofi Pasteur's sBLA for Fluzone Intradermal Quadrivalent vaccine for adults.....           Array BioPharma grants license to Oncothyreon for ONT-380.....           TWi gets approval for protocol of Phase II trial of AC-201 in US and Taiwan.....           ChemoCentryx reports positive results from Phase II diabetic nephropathy trial of CCX140.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences is the professional body for the Pharmaceutical Sciences in United Kingdom. A Pharmaceutical Scientist is an individual who contributes to bringing a new drug from concept through to a medicinal product. This includes, but is not exclusive to, individuals in academia, industry, regulation, clinical research and manufacturing.

The mission of the Academy of Pharmaceutical Sciences is to champion innovation and opportunity in Pharmaceutical Sciences for the delivery of medicines.

In order to achieve this mission, our aims are to:

  • Promote the Pharmaceutical Sciences to stakeholders to facilitate understanding and achieve engagement
  • Share learning, drive collaboration, partnership and innovation
  • Deliver insights into industry and academic roles for aspiring scientists
Latest News
DMU Free Evening Seminar: QbD for Biopharmaceuticals: Progress and Opportunities
MONDAY, 8 DECEMBER 2014
16:30 – 19:30 Tuesday 13th January 2015 MedImmune, Cambridge GUEST SPEAKERS Tim Schofield, MedImmune Keith Chidwick, MHRA Bruno Boulanger, Arlenda PROGRAMME 16:30Arrive and tea and coffee17:00Opening Remarks, Paul Varley, VP, Biopharmaceutical Development, MedImmune17:05Introduction by De Montfort University17:15Timothy Schofield, Senior Fellow, Regulatory Sciences & Strategy, Analytical Biotechnology, MedImmune17:50Keith Chidwick, Senior Pharmaceutical Assessor, MHRA18:20 Bruno Boulanger, Professor at University of Liège, Belgium, CSO at Arlenda SA.18:45Closing remarks18:50Networking drinks and canapés De Montfort University’s Quality by Design group would like to invite you to attend the launch event for our new distance learning module in Quality by Design for Biopharmaceuticals. The event will provide a chance to learn more about the DMU QbD distance learning course, to learn from the experiences of our guest speaker and to network with other biopharmaceutical scientists and professionals.. Places are limited so reserve your place today: Email: qbd@dmu.ac.uk. For further information about the DMU’s new Biopharmaceuticals module see: http://www.qbd-dmu.co.uk/biopharmaceuticals-module/. For further information about QbD at DMU go to: dmu.ac.uk/qbd. Enrolling now for distance learning courses in Quality by Design. Visit www.dmu.ac.uk/qbd to find out more! .
Cross-Industry Organizations: An update on activities of the Drugs in the Lung Network in inhalation
THURSDAY, 27 NOVEMBER 2014
The Drugs in the Lung Network was devised with the aim of providing cross-company collaboration and developing industry-academia pre competitive consortia. It acts as a sub group of the Inhalation Focus Group, and has published an article in Inhalation reviewing recent events and looking forward to 2015/2016. Click here for more information and a copy of the article. http://www.apsgb.co.uk/focus_groups/overview.asp?TeamCode=IN12. .
APS Freeze Drying and Alternative Drying Technologies for Parenterals
FRIDAY, 14 NOVEMBER 2014
Burleigh Court, Loughborough Wednesday 28th January 2015. The meeting is being organised jointly by two of the APS focus groups, Parenterals Focus Group and Biotherapeutics and Vaccines Focus Group. The meeting will look at the latest challenges and opportunities in the preservation of biopharmaceuticals. It will cover both conventional freeze drying but also look at alternative technologies such as spray drying and Super Critical Fluid (SCF) drying. There will be presentations on the:. Impact and selection of Process.. Analytical Technologies for freeze drying,. The incorporation of ice nucleation as at tool for shortening processing times and improving batch homogeneity.. Impact of formulation selection and the industrial application of spray drying in biotherapeutics.. Application of Super Critical Fluid drying in biotherapeutics.. Speakers will include:. Patrick Garidel (Boerringher Ingelheim, Germany), Geoff Smith (DeMontfort University), Kevin Ward, (Biopharma), Richard Kaye (GSK), Daryl Williams (Imperial University) Peter York (Crystec Pharma). There will also be an exhibitor’s showcase by companies working in this area. The event is suitable for both scientists and leaders in the pharmaceutical arena as well as other processing industries who have a particular interest in the formulation, processing and analysis of biopharmaceuticals.. For more information and to register, please visit us online at:. http://www.apsgb.co.uk/EVENTS/20150128/Default.asp. .
The European Paediatric Formulation Initiative (EuPFI) paediatric biopharmaceutics survey
WEDNESDAY, 22 OCTOBER 2014
The EuPFI (European Paediatric Formulation Initiative www.eupfi.org) are looking to gather the views of biopharmaceuics scientists on the development of a paediatric biopharmaceutics classification system.. If you are an individual working in the area of biopharmaceutics, we would really appreciate your time in completing this short survey. Note that we would like individuals to complete this based on their own opinions and not necessarily those of their employer. Feel free to share this with others working in this area.. xhttps://www.survey.bris.ac.uk/bham/eupfi-biopharm-bcs . We anticipated that this will take 10-15 minutes and we plan to share our findings via the EuPFI but please leave your contact details within the questionnaire if you would like a direct mail regarding the output.. With many thanks for your time. The EuPFI Biopharmaceutics workstream.
 
Follow us
 
Upcoming Events
APS Freeze drying and alternative drying technologies for parenterals
28 January 2015
APS Bioequivalence of Orally Inhaled Drug Products: Joint Meeting with The Aerosol Society
30 March 2015
APS Particle Engineering - Joint Meeting with SSPC
13 - 14 April 2015
APS Industrial Insights 2015
16 - 17 April 2015
APS Board Meeting
28 - 29 April 2015
Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.